Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Initial Axillary Lymph Node Metastasis after Primary Systemic Therapy.
10.4048/jbc.2011.14.2.147
- Author:
Eunyoung KANG
1
;
Il Yong CHUNG
;
Sang Ah HAN
;
Sun Mi KIM
;
Mijung JANG
;
Chae Yeon LYOU
;
So Yeon PARK
;
Jee Hyun KIM
;
Yu Jung KIM
;
Sung Won KIM
Author Information
1. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. brcakorea@gmail.com
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Primary systemic therapy;
Sentinel lymph node biopsy
- MeSH:
Breast;
Breast Neoplasms;
Humans;
Lymph Node Excision;
Lymph Nodes;
Neoplasm Metastasis;
Nitriles;
Pyrethrins;
Sentinel Lymph Node Biopsy
- From:Journal of Breast Cancer
2011;14(2):147-152
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Primary systemic therapy (PST) downstages up to 40% of initial documented axillary lymph node (ALN) metastases in breast cancer. The current surgical treatment after PST consists of breast tumor resection and axillary lymph node dissection (ALND). This strategy, however, does not eliminate unnecessary ALND in patients with complete remission of axillary metastases. The aim of this study was to examine the accuracy of sentinel lymph node biopsy (SLNB) after PST among patients with documented ALN metastasis at presentation and to identify the rate of pathologic complete-remission (CR) with ALN after PST. METHODS: We analyzed 66 patients with ALN metastasis that was pathologically proven preoperatively who underwent SLNB and concomitant ALND after PST. Axillary ultrasound (AUS) was used to evaluate the clinical response of initially documented ALN metastasis after PST. Intraoperative lymphatic mapping was performed using blue dye with or without radioisotope. RESULTS: After PST, 34.8% of patients had clinical CR of ALN on AUS and 28.8% patients had pathologic CR of ALN. The overall success rate of SLNB after PST was 87.9%, and the sentinel lymph node identification rate in patients with clinical CR was 95.7%. In patients with successful lymphatic mapping, 70.7% of patients had residual axillary metastases. The overall accuracy and false-negative rate were 87.9% and 17.1% in all patients: 95.5% and 10.0% in patients with clinical CR of ALN, and 83.3% and 19.4% in patients with residual axillary disease after PST. CONCLUSION: Our findings suggest that SLNB may be feasible in patients with initial documented ALN metastasis who have clinical CR for metastatic ALN after PST. Further investigation in a prospective setting should be performed to confirm our results.
